Curesponse and Rafael to collaborate on integrating Artificial Intelligence capabilities in precision oncology platform. This collaboration combines Rafael’s vast array of combat-proven AI and Machine Learning capabilities with Curesponse’s cutting-edge, personalized oncology technologies in the fields of Drug Response, the Tumor Microenvironment (TME), and Molecular Biology to bring a unique, accurate and combined Genomic-Functional drug sensitivity platform to cancer patients.
Menu